Trial Profile
An Open-label, Mass Balance Study to Investigate the Absorption, Metabolism and Excretion of [14C]-MT-8554 After a Single Oral Dose to Healthy Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 May 2023
Price :
$35
*
At a glance
- Drugs Elismetrep (Primary)
- Indications Diabetic neuropathies; Neurological disorders; Vasomotor symptoms
- Focus Pharmacokinetics
- Acronyms MT-8554 MB
- Sponsors Mitsubishi Tanabe Pharma America
- 13 Feb 2018 Status changed from recruiting to completed.
- 09 Jan 2018 Status changed from not yet recruiting to recruiting.
- 29 Dec 2017 New trial record